Clinical trial comparing prasugrel to clopidogrel following percuataneous coronary intervention is ended early due to overall low rate of primary endpoint clinical events

A clinical trial comparing prasugrel to clopidogrel for patients with high on-clopidogrel platelet reactivity (HCPR) following percutaneous coronary intervention (PCI) was ended early due to relatively few occurrences of cardiac death or myocardial infarction -- the primary endpoint -- at six month follow up.

Read the whole article on Science Daily

More from Science Daily